30 related articles for article (PubMed ID: 8996226)
1. Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits.
Gezer AO; Kochmanski J; VanOeveren SE; Cole-Strauss A; Kemp CJ; Patterson JR; Miller KM; Kuhn NC; Herman DE; McIntire A; Lipton JW; Luk KC; Fleming SM; Sortwell CE; Bernstein AI
Neurobiol Dis; 2020 Jul; 141():104947. PubMed ID: 32422283
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the Paraquat-Induced Sporadic Parkinson's Disease-Like Model.
Bastías-Candia S; Zolezzi JM; Inestrosa NC
Mol Neurobiol; 2019 Feb; 56(2):1044-1055. PubMed ID: 29862459
[TBL] [Abstract][Full Text] [Related]
3. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.
Guzman JN; Ilijic E; Yang B; Sanchez-Padilla J; Wokosin D; Galtieri D; Kondapalli J; Schumacker PT; Surmeier DJ
J Clin Invest; 2018 Jun; 128(6):2266-2280. PubMed ID: 29708514
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of targeting glutamate receptors in Parkinson's disease.
Finlay C; Duty S
J Neural Transm (Vienna); 2014 Aug; 121(8):861-80. PubMed ID: 24557498
[TBL] [Abstract][Full Text] [Related]
5. MPTP mouse models of Parkinson's disease: an update.
Meredith GE; Rademacher DJ
J Parkinsons Dis; 2011; 1(1):19-33. PubMed ID: 23275799
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S
CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
[TBL] [Abstract][Full Text] [Related]
7. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].
Ossola B; Schendzielorz N; Chen SH; Bird GS; Tuominen RK; Männistö PT; Hong JS
Neuropharmacology; 2011 Sep; 61(4):574-82. PubMed ID: 21586298
[TBL] [Abstract][Full Text] [Related]
8. The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons.
Mouton PR; Kelley-Bell B; Tweedie D; Spangler EL; Perez E; Carlson OD; Short RG; deCabo R; Chang J; Ingram DK; Li Y; Greig NH
Neurobiol Aging; 2012 Feb; 33(2):423.e27-36. PubMed ID: 21093964
[TBL] [Abstract][Full Text] [Related]
9. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.
Kachroo A; Irizarry MC; Schwarzschild MA
Exp Neurol; 2010 Jun; 223(2):657-61. PubMed ID: 20188092
[TBL] [Abstract][Full Text] [Related]
10. Glutamate receptors as therapeutic targets for Parkinson's disease.
Johnson KA; Conn PJ; Niswender CM
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
[TBL] [Abstract][Full Text] [Related]
11. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Hu X; Zhang D; Pang H; Caudle WM; Li Y; Gao H; Liu Y; Qian L; Wilson B; Di Monte DA; Ali SF; Zhang J; Block ML; Hong JS
J Immunol; 2008 Nov; 181(10):7194-204. PubMed ID: 18981141
[TBL] [Abstract][Full Text] [Related]
12. Animal models of Parkinson's disease progression.
Meredith GE; Sonsalla PK; Chesselet MF
Acta Neuropathol; 2008 Apr; 115(4):385-98. PubMed ID: 18273623
[TBL] [Abstract][Full Text] [Related]
13. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.
Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW
J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604
[TBL] [Abstract][Full Text] [Related]
14. The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.
Pedersen V; Schmidt WJ
Neurotox Res; 2000; 2(2-3):179-204. PubMed ID: 16787840
[TBL] [Abstract][Full Text] [Related]
15. Strategies for the protection of dopaminergic neurons against neurotoxicity.
Gerlach M; Double KL; Youdim MB; Riederer P
Neurotox Res; 2000; 2(2-3):99-114. PubMed ID: 16787835
[TBL] [Abstract][Full Text] [Related]
16. Evidence for neurogenesis in the adult mammalian substantia nigra.
Zhao M; Momma S; Delfani K; Carlen M; Cassidy RM; Johansson CB; Brismar H; Shupliakov O; Frisen J; Janson AM
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7925-30. PubMed ID: 12792021
[TBL] [Abstract][Full Text] [Related]
17. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.
Chan P; Di Monte DA; Langston JW; Janson AM
J Pharmacol Exp Ther; 1997 Jan; 280(1):439-46. PubMed ID: 8996226
[TBL] [Abstract][Full Text] [Related]
18. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
19. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
